CAMKK2

Across TCGA pan-cancer cohorts, CAMKK2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CAMKK2 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CAMKK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAMKK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, BLCA, and PRAD are the cancer types where CAMKK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.086	0.555	<.001	36	view →
BLCA	OS	Median	All	0.175	0.610	.001	24	view →
PRAD	DFS	Median	All	0.617	0.886	.038	6	view →
ESCA	OS	Median	II,III,IV	0.360	0.706	.023	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.488	.042	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	III,IV	0.114	0.405	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CAMKK2–LIHC (DFS)

Open the LIHC breakdown →